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Abstract
Background: During clinical trials, researchers rarely question nominal doses specified on labels of investigational
products, overlooking the potential for inaccuracies that may result when calculating pharmacokinetic and
pharmacodynamic parameters. This study evaluated the disparity between nominal doses and the doses actually
administered in two Phase I trials of a biosimilar drug.
Methods: In Trial A, 12 healthy volunteers received various doses of an interferon β-1a biosimilar via either subcutaneous
or intravenous injection, prepared by partially emptying 0.53 ml syringes supplied by the manufacturer. In Trial B,
12 volunteers received three different formulations of the drug via intravenous injection (biosimilar with and
without albumin and a comparator), followed by multiple subcutaneous injections. In both trials, the dose administered
was calculated as D = C × V − losses, where C is the drug concentration assessed using ELISA, V is the volume
administered calculated using syringe weighing and losses are deduced from in-vitro experiments. Interferon binding to
added albumin and infusion lines was evaluated using a 125I-interferon tracer with gel-filtration chromatography.
Results: In Trial A, measured concentrations were close to the nominal strength indicated by the manufacturer
(median bias: −6 %), whereas in Trial B they differed significantly for all three formulations (median biases: +67 %, +73 %
and +31 % for the biosimilar with albumin, the biosimilar without albumin and the comparator, respectively). In Trial A,
the doses actually administered showed large variability and biases, especially at the lowest doses. Indeed, actually
injected volumes differed by as much as 74 % from theoretical volumes – a phenomenon mainly attributed to
unnoticed fluid re-aspiration through the syringe needle. This was corrected in Trial B. Interferon was not significantly
adsorbed on the infusion lines used for intravenous administration. Its binding to albumin was slow, reaching 50 %
after a 16 h incubation.
Conclusions: These examples illustrate the importance of assessing the actual doses administered in clinical trials, to
ensure accuracy in the determination of clearance, distribution volume, bioavailability and dose–response relationships.
Trial registration: Clinicaltrials.gov NCT02515695 (Trial A) and NCT02517788 (Trial B). Registered on 24 July and 5
August 2015, respectively.
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Background
Over the past few decades, the assessment of a new drug’s
pharmacokinetic properties has become a recognized pre-
requisite for its rational use in therapy. Pharmacokinetic
and pharmacodynamic factors are now understood to be
among the commonest explanations of undesired variability
in drug response. However, a literature review revealed a
striking contrast between the great attention devoted to
analytical methods and the mathematical modelling of phar-
macokinetic data in clinical trials, and the lack of care paid
to the pharmaceutical aspects of drug administration [1].
Many clinical researchers simply assume that the dose is
the nominal amount declared on the drug’s label, overlook-
ing noticeable biases that inaccuracies may introduce in the
assessment of pharmacokinetic parameters [1]. For example,
calculation of clearance (CL) depends directly on the dose:
CL ¼ D
AUC
where D is the dose and AUC the area under the
plasma concentration-time curve.
We have previously proposed six criteria with which
to identify clinical trials that might be especially at risk
of an error when measuring drug concentrations in body
fluids (Table 1) [1]. A retrospective literature analysis of
193 articles showed that about one quarter of clinical tri-
als met at least three of these criteria, indicating a clear
need for more accurate assessments of the doses admin-
istered to subjects. However, only 5 % (9/193) mentioned
any type of verification of the actual dose administered
[1]. Indeed, accurate determination of administered doses
is rarely, if at all, included in current trial procedures.
In a medical care context, such issues may have clinical
consequences, and unexpected discrepancies between the
expected and measured concentrations in drug infusions
are not exceptional [2–5]. Until now, to the best of our
knowledge, this topic has never been assessed in the con-
text of a clinical trial for biological drugs, whether original
or biosimilar.
This investigation thus aimed to evaluate, pragmatically,
the biases related to inaccuracies in the dosing of a new
biosimilar drug, administered during two Phase I trials.
Methods
We performed our pharmaceutical evaluations during
two Phase I clinical studies (Trials A and B). Both were
randomized trials of a crossover design comparing various
injection routes, dose levels and formulations of interferon
β-1a. The investigations were double-blinded for dose but
not for route. The trials’ objectives were to assess the
pharmacokinetic and pharmacodynamic profiles of the
new biosimilar drug (including linearity and absolute bio-
availability), compare the biosimilar drug with the original
drug brand and investigate the possible influence of albu-
min added to the formulation. All participants gave in-
formed consent in accordance with the principles of the
Declaration of Helsinki. The study protocols, informed
consent forms and related documents were approved by
the Human Research Ethics Committee of the Canton
Vaud (Lausanne, Switzerland) and by the Swiss Agency for
Therapeutic Products (Swissmedic, Bern, Switzerland).
Trial design
In Trial A, 12 healthy volunteers received single doses,
either subcutaneously (1.5, 3.0, 6.0 or 12.0 MIU) or
intravenously (0.5, 1.0, 2.0 or 4.0 MIU), of a biosimilar
interferon β-1a devoid of human serum albumin (HSA)
(Biferonex® HSA-free, manufactured by Rentschler Bio-
technologie GmbH, Laupheim, Germany, on behalf of
BioPartners, Baar, Switzerland). In Trial B, 12 other
volunteers received three different formulations of the
drug in crossover by slow intravenous injection (the bio-
similar drug devoid of albumin [Biferonex® HSA-free],
the biosimilar drug with added albumin [Biferonex® +HSA]
and the original comparator [Rebif®, Merck Serono, Geneva,
Switzerland]). Subsequently, over 8 days and in parallel,
these volunteers received subcutaneous injections every
second day, of either Biferonex® HSA-free or Rebif®.
Study drugs
In both trials, the manufacturer supplied biosimilar
Biferonex® as an aqueous isotonic buffered solution of
interferon β-1a 6.0 MIU/0.53 ml (overfill of 0.03 ml),
stabilized with methionine (pH = 6.8). The pre-filled
sterile syringes were equipped with a sealed needle and a
protective sheath, ready for subcutaneous injection. This
was the planned form for commercialization. In Trial B,
the comparator solution (Rebif®) was provided in pre-
filled sterile syringes of 6.0 MIU/0.50 ml, ready for sub-
cutaneous administration.
Dose preparation
In Trial A, a wide range of nominal doses (0.5 to 12.0
MIU) was administered to assess the pharmacokinetic and
pharmacodynamic dose proportionalities. As the manufac-
turer only provided syringes of 6.0 MIU/0.53 ml, the nom-
inal doses were prepared by partially emptying the syringes
Table 1 Criteria for identifying clinical trials that may benefit
from accurate determination of doses administered
1 Studies to determine a drug’s absolute clearance or volume
parameters
2 Studies in which a drug is administered intravenously
3 Studies using a drug not manufactured according to industrial
standards
4 Studies on peptides, proteins or other complex biological agents
5 Studies using immunologically based analytical methods
6 Studies using a parallel-group design, with qualitatively different
treatments administered to each group
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by drop count. The manufacturer had previously checked
that 12 pre-filled syringes delivered a mean (± standard de-
viation) of 102 ± 4 drops when held vertically (i.e. 1.2 MIU/
0.1 ml or 58,824 U/drop). This information allowed us to
make an on-the-spot calculation of the number of drops to
be removed in order to obtain the target doses.
In Trial B, the dose administered was always 18.0
MIU, corresponding to three 6.0 MIU pre-filled syringes
for both Biferonex® HSA-free and Rebif®. For the prepar-
ation of Biferonex® + HSA solutions, the contents of
three syringes were added to a sterile 5.0 ml glass vial
containing 1.6 ml of HSA solution at 30 mg/ml. The
preparation was stirred gently to ensure a homogenous
mixture without foam formation and left in the vial at
room temperature to enable the formation of a stable al-
bumin-interferon complex. Finally, the available volume
was aspired from the vial using a 5 ml syringe (subse-
quently protected by a needle sheath).
Dose accuracy assessment
In both trials, the actual dose administered was calcu-
lated as:
D ¼ C  V−losses
where C is the solution’s concentration,V the solution’s vol-
ume and ‘losses’ represents the amount of drug bound to
syringes, infusion lines, containers, etc., as evaluated via in-
vitro experiments. Indeed, peptides such as interferon can
adsorb onto many types of plastic and glass used for deliv-
ery [6, 7], especially in the absence of stabilizing proteins,
such as plasma or HSA [8]. We thus decided to validate
both the concentration of drug solutions and the proce-
dures for dose preparation and injection. With this intent,
two in-vitro investigations (Experiments 1 and 2) were per-
formed prior to clinical trials A and B. A system was de-
signed to compare the amounts of interferon recovered in
an albumin/saline solution after direct delivery (i.e. mimick-
ing subcutaneous injection) versus injection through an in-
fusion line (i.e. mimicking intravenous injection; Fig. 1).
Human serum albumin was used to imitate the function of
blood and to limit drug adsorption onto the flask. Experi-
ment 1 was performed in triplicate at three dose levels (0.5,
1.0 and 4.0 MIU); Experiment 2 was performed in duplicate
at a dose level of 18.0 MIU for the three different formula-
tions (Biferonex® HSA-free, Biferonex® +HSA and Rebif®).
Any amounts missing after infusion through the catheter
and line, compared with direct delivery, would indicate the
existence of an adsorption phenomenon along the infusion
line and provide a quantitative estimate of the amount of
drug absorbed. Any dose-dependency for this adsorption
would be shown using ANOVA on log-transformed values
to compare relative losses at the different dose levels. Dur-
ing Experiment 1, the solutions were collected in two sorts
of tube (type I glass vials and polypropylene tubes,
Sarstedt®, Nümbrecht, Germany) to exclude any adsorp-
tion on the tube walls and to select the best option for
the clinical trials – preliminary tests had shown that
polystyrene tubes bound interferon β-1a.
The concentration C of interferon β-1a in the solu-
tions used during the trials and in-vitro experiments was
assessed using the same immunological assay applied to
the clinical pharmacokinetic samples (ELISA kit, Bio-
Source®, Carlsbad, NM, USA). The actual concentrations
of Biferonex®, as assessed by the manufacturer using its
validated cytopathic assay, was 6.9 MIU/0.53 ml for Trial A
and Experiment 1, 6.6 MIU/0.53 ml for intravenous prepa-
rations in Trial B and Experiment 2 and 5.9 MIU/0.53 ml
for subcutaneous preparations in Trial B.
The administered volume V was assessed by systematic-
ally weighing all syringes before and after intravenous or
subcutaneous administration. To calculate V, the weight (W)
difference:
W i ¼ WBefore i−WAfter i
was divided by the solution’s relative density (0.9983 for















Fig. 1 Experiments 1 and 2: in vitro simulation of the intravenous
(i.v.) injection process
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0.9950 for Rebif®). Experiments 1 and 2 enabled estima-
tion of the variability of actual doses injected at each
dose level. During the clinical trials, the actual weights
Wi injected into volunteers were also compared with the
corresponding theoretical weights (TWi, calculated by
multiplying the theoretical volume for injection for a
given dose by the relative density) to assess the bias and
the variability of the doses administered.
Profile of drug binding to albumin
Finally, as part of Trial B, a third in-vitro experiment ex-
amined whether the binding of HSA to biosimilar inter-
feron β-1a was time-dependent, as a slow binding rate
could jeopardize the utility of the resemblance between
Biferonex® + HSA and the original comparator, Rebif®.
Should biosimilar interferon β-1a remain partly unbound,
then it would be more available for binding to target re-
ceptors and to subsequent receptor-mediated clearance.
The manufacturer provided an ad-hoc solution of the
biosimilar drug at a concentration of 0.299 mg/ml (70.3
MIU/ml) in aliquots of 1.67 ml (0.5 mg) containing
4 mM methionine. Interferon β-1a was labelled with 125I
by ANAWA (Wangen, Switzerland) and prepared in ly-
ophilized aliquots of 2.5 μCi, each containing 25 ng of
interferon β-1a. The stock solution of interferon β-1a at
70.3 MIU/ml was diluted to prepare a solution of 12 MIU
in a volume of 0.53 ml, which was directly added to the
vials containing 2.5 μCi of labelled interferon β-1a.
The experiment involved co-incubating 125I-labelled
interferon β-1a with HSA at the concentration used for
the clinical trial (0.3 %) over different incubation periods
(1 h 15 min, 2 h 30 min, 3 h 45 min, 5 h 15 min and
16 h). Rebif® was also used at a concentration of 6.0
MIU in 0.50 ml directly added into a vial containing
2.5 μ Ci of interferon β-1a and incubated for 5 h 15 min
and 16 h.
The fraction of interferon β-1a bound to HSA was then
separated from the free form using gel-filtration chroma-
tography. With this intent, 25 μl of co-incubation mixture
was injected onto a fast protein liquid chromatography
column Superose 12 (Pharmacia, Uppsala, Sweden) at a
flow rate of 0.6 ml/min using a phosphate buffered saline
mobile phase. Fractions were collected every 2 min and
radioactivity was measured using a gamma counter (LKB,
Mt Waverley, Australia).
Finally, a dose of 125I-labelled interferon β-1a was
injected through the infusion catheter and line (such
as in Fig. 1) to confirm the findings of Experiments 1
and 2.
Results
Losses during syringe manipulation and intravenous
injection
Experiments 1 and 2 both showed that interferon β-1a
was not significantly adsorbed on the infusion line and
catheter used for intravenous administration, and was
only marginally adsorbed to the syringe (see Tables 2
and 3). In Experiment 1, no losses were induced by col-
lection in either polypropylene tubes (Sarstedt®) or type
1 glass vials (data not shown).
An injection of 125I-labelled interferon β-1a through
the same catheter and line confirmed the recovery of
96 % of the radioactivity, whereas 3.6 % and 0.4 %
remained bound to the syringe used for administration
and to segments of the line, respectively.
Drug solution concentration
In Experiment 1, the concentration experimentally de-
termined using ELISA was remarkably close to the man-
ufacturer’s declared value (median relative concentration
94 %, with a range of 47 %, see Table 2). In contrast, the
concentrations determined in Experiment 2 differed sig-
nificantly from the manufacturer’s declaration, with a
median relative concentration of 168 % (range 12 %) for
Biferonex® (with and without HSA), and of 131 % (range
19 %) for Rebif® (Table 3).
Dose accuracy
In vitro, for a nominal dose of 0.5 MIU, the median ac-
tual dose of Biferonex® HSA-free, assessed using syringe
weighing, differed by more than 10 % (although not at
higher doses, see Tables 2 and 3). In Experiment 2, for a
theoretical level of 18.0 MIU, the median actual doses of
Biferonex® + HSA and Rebif® were 16.7 MIU and 18.3
MIU, respectively.
Table 2 Experiment 1: losses after intravenous injection of Biferonex®, relative concentrations and actual doses after direct
subcutaneous injection at various dose levels




Median Range Median Range Median Range
0.5 −4.3 % 22.3 % 93 % 34 % 0.57 0.13
1.0 −10.6 % 31.9 % 115 % 29 % 1.10 0.02
4.0 −7.3 % 15.6 % 94 % 16 % 4.38 0.10
Losses observed after injection through the infusion line (intravenous) versus direct injection (subcutaneous) of Biferonex® HSA-free at different dose levels. A negative
value represents an apparent gain. Relative concentrations are expressed with reference to nominal levels
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In Trial A, the median relative biases in the weight of
Biferonex® solution injected into the volunteers ranged
from −74 % to +6.1 % (at dose levels of 0.5 and 6.0 MIU,
respectively). Median relative biases were typically nega-
tive below 4.0 MIU and positive above (Table 4). The
median relative biases evaluated during Trial B, using
three formulations of interferon β-1a at 18.0 MIU,
ranged from −4.2 % to 7.5 % (Table 5).
Profile of drug binding to albumin
During Experiment 3, the free form of 125I interferon
β-1a in NaCl solution eluted between fractions 36 and
42 in gel-filtration chromatography. Increasing amounts
of radioactivity, corresponding to high molecular weight
HSA complexed with 125I interferon β-1a, eluted in
fractions 6–12 after 1 h 15 min (15 % binding), 2 h
30 min (18 %), 3 h 45 min (20 %), 5 h 15 min (33 %)
and 16 h of incubation (46 %). In the presence of Rebif®
increasing amounts eluted too after 5 h 15 min (30 %
binding) and 16 h of incubation (44 %). The heavier
fraction containing radioactivity was confirmed using
ELISA as representing immunoreactive interferon
β-1a.
Discussion
This investigation evaluated the different sources of bias
that might affect the doses of an experimental parenteral
biological drug administered in two Phase I clinical trials.
Losses during syringe manipulation and intravenous
injection
Experiments 1, 2 and 3 revealed no significant losses of
interferon β-1a to syringes and infusion lines in intraven-
ous administration. Nor was interferon β-1a significantly
adsorbed onto Sarstedt® polypropylene tubes, which could
thus be used throughout the clinical trials and during
Experiments 2 and 3.
Concentration of the drug solution
The concentration of Biferonex® HSA-free assessed using
ELISA in Experiment 1 was in the range of 15 % of the
nominal dose, whereas Experiment 2 showed a 68 % ex-
cess. This significant discrepancy was unexpected. In-
deed, cytopathic assays only reported modest differences
between Biferonex® batches (<10 % with 6.6 MIU for
Experiment 1 and Trial A; 5.9 MIU for Experiment 2
and Trial B). It is, however, not surprising that similar-
ities revealed by a bioassay do not translate directly into
similarities in an immunoassay. Although an exact con-
centration for the reference formulation Rebif® was
lacking (no certificate of analysis was available), our as-
sessment revealed a 31 % excess of ELISA-based con-
centration with regard to nominal strength.
Drug dose accuracy
Experiment 1 revealed some variability in the actual dose
administered after ‘drop count’ preparation and showed
this method to be rather inaccurate at lower doses – this
Table 3 Experiment 2: losses after intravenous injection, relative concentrations and actual doses after direct subcutaneous injection
of different formulations of interferon β-1a




Median Range Median Range Median Range
Biferonex® HSA-free 5.6 % 0.6 % 167 % 3 % 18.01 0.02
Biferonex® + HSA 13.6 % 6.5 % 173 % 8 % 16.74 0.05
Rebif® 5.7 % 9.1 % 131 % 19 % 18.33 0.01
Losses observed after injection through the infusion line (intravenous) versus direct injection (subcutaneous) of three different formulations of interferon β-1a at a
dose of 18.0 MIU. Relative concentrations are expressed with reference to nominal levels
Table 4 Trial A: bias and variability in the amount of injected Biferonex® at different dose levels
Dose level [MIU] TWi Wi Median relative bias Route
[mg] [mg] Bias [%] Range
0.5 41.6 20.8 −73.6 % 205.1 % Intravenous
1.0 83.2 50.5 −51.0 % 119.8 % Intravenous
1.5 124.8 106.5 −15.1 % 30.3 % Subcutaneous
2.0 166.4 154.3 −8.1 % 23.9 % Intravenous
3.0 249.6 239.7 −5.4 % 9.7 % Subcutaneous
4.0 332.8 326.2 −1.3 % 11.8 % Intravenous
6.0 499.2 529.1 6.1 % 4.0 % Subcutaneous
Biases evaluated during Trial A with Biferonex® HSA-free at each dose level. TWi = weight of solution to inject; Wi = weight actually injected, bias = median of (Wi −
TWi)/TWi, with the range covered by individual measures
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was despite the fact that this is the manufacturer’s pro-
posed method for the preparation of a wide range of
nominal doses (0.5 to 6.0 MIU). The use of drop count
preparation during clinical Trial A would thus have re-
sulted in an erroneous estimation of the amounts of the
drug actually administered, especially compared with the
precise measurement of an injected weight of drug solu-
tion. Conversely, in Experiment 2, where the entire volume
contained in a syringe was injected, the actual doses of
Biferonex® (with and without HSA) and of Rebif® were
accurate.
A further significant issue was identified regarding in-
consistencies between the theoretical weights to be ad-
ministered (TWi, the product of nominal volume and
relative density) and the weights of injected solution ac-
tually measured during Trial A (Wi). The median bias
was systematically negative for doses ranging from 0.5 to
4.0 MIU, but did not exceed the weight of eight drops
(42 mg, i.e. 8 % of total syringe volume). At the lowest
dose level – 0.5 MIU – administered in this trial, this
led to a median relative bias of 74 %, with a huge range
of 205 %. Indeed, a thorough examination of the injection
procedure revealed that more than 30 mg of aqueous solu-
tion could be re-aspired into the syringe from the injection
site if no pressure was applied to the piston while removing
the needle. This re-aspiration phenomenon is due to the
spontaneous re-expansion of the elastic piston in the conic
section of the syringe end. During Trial A, our determina-
tions of injected intravenous doses through careful syringe
weighing were thus altered by a systematic negative bias
resulting from the re-aspiration of a significant volume
of saline solution, which mimicked incomplete injec-
tions (Fig. 2).
After Trial A, the weight of the re-aspired solution,
measured a posteriori in all the intravenous syringes
(retained in accordance with the rules of Good Clinical
Practice), was systematically determined and subtracted
from the weight initially determined after injection (Wi).
This unexpected finding and its ensuing correction
allowed precise doses administered to volunteers to be
determined. Conversely, the residual weights quantified
in the subcutaneous syringes in Trial A were deemed to
Table 5 Trial B: biases and variability in the amount of injected formulations of interferon β-1a
Formulation TWi Wi Median relative bias Route
[mg] [mg] Bias [%] Range
Biferonex® HSA-free 1497.5 1593.9 6.8 % 2.7 % Intravenous
Biferonex® HSA-free 1497.5 1608.4 7.5 % 4.8 % Subcutaneous
Biferonex® + HSA 3060.0 2918.5 −4.2 % 7.2 % Intravenous
Rebif® 1497.5 1538.7 2.9 % 2.4 % Intravenous
Rebif® 1497.5 1548.8 3.6 % 2.9 % Subcutaneous
Biases evaluated during Trial B with three different formulations at a dose of 18.0 MIU. TWi = weight of solution to inject, Wi = weight actually injected, bias =median of
(Wi − TWi)/TWi, with the range covered by individual measures
Syringe at the end of injection, 
pressure maintained on the piston 
Syringe at the end of injection, 
pressure released before syringe drawback. 
aspiration of saline solution occurs 
A backwards retraction of the piston with re-
Fig. 2 Saline solution re-aspiration after intravenous injection through the infusion line
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correspond mainly to re-aspired drug solution, and were
thus considered incomplete injections. Therefore, the
weight of subcutaneous injected solution (Wi) was kept
unchanged in final dose calculations.
To prevent this bias in the subsequent study (Trial B),
the investigators applied a strict procedure to maintain
the syringe piston depressed manually under full pres-
sure after injection and until removal of the needle.
Consequently, volume-related biases remained limited.
Profile of drug binding to albumin
Experiment 3 revealed that 125I-interferon β-1a binds
slowly to albumin, reaching about 30 % binding after 5 h
of incubation and almost 50 % after 16 h of incubation.
This incubation duration was therefore retained for the
preparation of the Biferonex® + HAS solution used in Trial
B, as it resulted in a degree of binding close to the com-
parator, Rebif® (formulated with HSA). The precise mo-
lecular interaction between HSA and interferon β-1a is
unknown. Taking into account its slow kinetics while
adding HSA to the biosimilar probably enabled us to
best mimic the reference brand and to avoid potential
biases linked to a difference in the free fraction.
Conclusions
These practical examples, especially regarding biases in
actual concentrations (Experiment 2) and volumes injected
(Trial A), illustrate that the issue of assessing doses actually
administered during clinical trials deserves serious atten-
tion, particularly those involving biological drugs. Careful
dose determination is essential to ensure accuracy in the
assessment of bioavailability, clearance, distribution vol-
umes or pharmacological potency, whether reported in the
scientific literature or in drug registration dossiers. When-
ever possible, the actual concentrations of the products
under investigation, rather than their nominal strength,
should be used in calculations, and doses should be cor-
rected for actually injected volumes.
Registration authorities should definitely address the
issue of the actual doses administered in their guidance
documents on how to carry out Phase I and II trials.
Clinical investigators, hospital pharmacists involved in
clinical trials and peer reviewers for biomedical journals
should all be made aware of this important component
of quality management in clinical research.
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